UK Markets closed

Atai Life Sciences N.V. (ATAI)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.0900-0.0800 (-2.52%)
At close: 01:00PM EST
3.2400 +0.15 (+4.85%)
After hours: 03:54PM EST

Atai Life Sciences N.V.

Krausenstrasse 9-10
Berlin 10117
49 89 2153 9035

Full-time employees87

Key executives

NameTitlePayExercisedYear born
Mr. Christian AngermayerFounder & Chairman of the Supervisory Board37.53kN/A1978
Mr. Florian BrandCo-founder & CEO627.77kN/A1987
Dr. Srinivas G. Rao M.D., Ph.D.Co-Founder & Chief Scientific Officer693.46kN/A1969
Dr. Rolando Gutierrez-Esteinou M.D.Chief Medical Officer615.38kN/A1961
Mr. Gregory L. Weaver CPA, M.B.A.Non-Employee AdvisorN/AN/A1956
Mr. Stephen B. BardinMD & CFON/AN/A1990
Ms. Anne JohnsonChief Accounting OfficerN/AN/AN/A
Ms. Madison CrawfordSr. Mang. of AccountingN/AN/AN/A
Mr. Aaqil AnwarMang. of Corp. Fin. & Investor RelationsN/AN/AN/A
Mr. Ryan BarrettSr. VP, Gen. Counsel & Company Sec.N/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

Corporate governance

Atai Life Sciences N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.